26718-25-2 Usage
Description
HALOFENATE is a selective peroxisome proliferator-activated receptor γ (PPARγ) modulator that possesses antidiabetic activity. It is a compound with the potential to regulate lipid metabolism and blood sugar levels, making it a promising candidate for the treatment of diabetes and related conditions.
Uses
Used in Pharmaceutical Industry:
HALOFENATE is used as an antihyperlipoproteinemic agent for managing high levels of lipids in the blood. Its action helps to reduce the risk of cardiovascular diseases associated with hyperlipidemia.
HALOFENATE is also used as a uricosuric agent to increase the excretion of uric acid in the urine, which is beneficial for the treatment of conditions like gout and hyperuricemia.
Used in Diabetes Management:
HALOFENATE is used as an antidiabetic agent for the treatment of diabetes. It modulates the PPARγ receptor, which plays a crucial role in regulating glucose homeostasis and insulin sensitivity, thereby helping to control blood sugar levels in diabetic patients.
Check Digit Verification of cas no
The CAS Registry Mumber 26718-25-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,7,1 and 8 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 26718-25:
(7*2)+(6*6)+(5*7)+(4*1)+(3*8)+(2*2)+(1*5)=122
122 % 10 = 2
So 26718-25-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)
26718-25-2Relevant articles and documents
METHODS FOR AVOIDING EDEMA IN THE TREATMENT OR PREVENTION OF PPARγ-RESPONSIVE DISEASES, INCLUDING CANCER
-
Page/Page column 77-78, (2008/06/13)
Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided.
